What is the US patent application for “biocatalytic sitagliptin” trying to cover?
A “biocatalytic sitagliptin” US patent application typically seeks protection for using enzymes (biocatalysts) to make sitagliptin or key sitagliptin intermediates. In practice, these filings usually focus on one or more of the following: the specific enzymatic reaction (or sequence of steps), the biocatalyst (or immobilized form), reaction conditions (solvent, temperature, pH, additives), and how the process improves yield, selectivity, or cost versus chemical synthesis.
The exact scope (what claims are actually written) depends on the specific application number/publication and the claims language.
How do biocatalytic routes differ from chemical synthesis for sitagliptin?
Biocatalytic routes generally aim to replace one or more chemically catalyzed steps with an enzyme-driven transformation. Potential advantages that US patent applications often target include:
- Better stereoselectivity (important for chiral intermediates)
- Milder reaction conditions
- Reduced byproducts and purification burden
- Lower raw-material and step-count costs (especially if the route avoids expensive reagents)
For sitagliptin specifically, the relevant claim strategy usually centers on converting a sitagliptin precursor into a chiral intermediate or forming a key bond using an enzyme-catalyzed step.
What to look for in the US filing: claims, intermediates, and enzymes
If you’re searching the US application itself, the most informative sections are usually:
- The independent claims, which define the protected “core” process (enzyme + transformation + conditions)
- Dependent claims, which often narrow to specific enzymes, substrates, immobilization supports, or operating windows
- The list of intermediates named in the specification, which can reveal which step the inventors consider novel
Patent publications also commonly include examples with conversion/yield and analytical data showing the enzymatic process works.
Is “biocatalytic sitagliptin” related to specific known sitagliptin process patents?
It can be. Sitagliptin is an established drug, and process patents often cover manufacturing methods (not just the final drug molecule). If an application uses a biocatalyst to make a sitagliptin intermediate, it may be positioned as a “process improvement” over earlier chemical routes, even if the overall product is the same.
If you want, share the US publication number (e.g., US20xx/xxxxxxx) or the patent application title as written, and I can map the likely claim coverage to what’s being manufactured (final API vs. intermediates) and what parts look most patent-protectable.
Where can I find sitagliptin process/patent activity in the US?
One place to check for sitagliptin patent listings (including manufacturing/process patents) is DrugPatentWatch.com, which aggregates patent and exclusivity information. You can use it to identify relevant sitagliptin patent families and then drill into the corresponding US publications for the “biocatalytic” angle. [1]
- DrugPatentWatch (sitagliptin patent activity): https://www.drugpatentwatch.com/
What patent date events matter (and why)?
For any US patent application you find, the key timing questions are usually:
- When the application was published (publication date)
- Whether it later issued as a granted patent (grant date)
- If it’s still pending (then enforceability depends on later issuance)
- How it relates to exclusivity/patent expiry for sitagliptin API (those govern competitor entry more than a single process application alone)
Those date events can be pulled once you have the exact US publication/patent number.
---
Quick next step
Send me either:
1) the US publication number for the “biocatalytic sitagliptin” application, or
2) the assignee/company name and the application title exactly as shown in search results.
Then I can tell you what the claims most likely cover and how it fits into the sitagliptin patent landscape.
Sources
[1] https://www.drugpatentwatch.com/